Conjugated Via Claimed Linking Group, Bond, Chelating Agent, Or Coupling Agent (e.g., Conjugated To Proteinaceous Toxin Via Claimed Linking Group, Bond, Coupling Agent, Etc.) Patents (Class 424/179.1)
-
Patent number: 12214050Abstract: Provided herein are conjugated immunoglobulins and methods for generating conjugated immunoglobulins using a microbial transglutaminase.Type: GrantFiled: August 20, 2021Date of Patent: February 4, 2025Assignee: Eisai R&D Management Co., Ltd.Inventors: Jared Spidel, Earl Albone
-
Patent number: 12168686Abstract: Compositions of TNF family of cytokines in covalently linked trimeric forms are disclosed. The resulting fusion proteins are secreted as disulfide bond—linked homotrimers, which are more stable in structure and therapeutically more efficacious than their native counterparts.Type: GrantFiled: October 16, 2022Date of Patent: December 17, 2024Assignee: Sichuan Clover Biopharmaceuticals, Inc.Inventor: Peng Liang
-
Patent number: 12134636Abstract: The present invention relates to a monoclonal antibody platform designed to be coupled to therapeutic peptides to increase the half-life of the therapeutic peptide in a subject. The invention also relates to pharmaceutical compositions and methods for use thereof.Type: GrantFiled: October 30, 2020Date of Patent: November 5, 2024Assignee: Janssen Pharmaceutica NVInventors: Mark Macielag, Raymond J. Patch, Rui Zhang, Martin A. Case, Mark J. Wall, Yue-Mei Zhang, Shamina M. Rangwala, James N. Leonard, Raul C. Camacho, Michael J. Hunter, Katharine E. D'Aquino, Wilson Edwards, Ronald V. Swanson, Wenying Jian, Ellen Chi
-
Patent number: 12128110Abstract: The present invention relates to a method for generating an antibody-payload conjugate by means of a microbial transglutaminase (MTG). The method comprises a step of conjugating a linker having a primary amine residue, said linker having the peptide structure (shown in N->C direction) (Aax)m-(Aax)(NH2)-(Aax)n-B-(Aax)o, or (Aax)m-B-(Aax)n-(Aax)(NH2)-(Aax)o, to a Gln residue comprised in the heavy or light chain of an antibody. Aax(NH2) is an amino acid, amino acid derivative or amino acid mimetic comprising a side chain having a primary amine group.Type: GrantFiled: September 19, 2018Date of Patent: October 29, 2024Assignee: PAUL SCHERRER INSTITUTInventors: Philipp Spycher, Roger Schibli, Martin Behe, Jori Wehrmuller
-
Patent number: 12128092Abstract: The present invention provides, among other things, pre-lyophilization formulations, reconstituted formulations, and lyophilate powder compositions comprising a Factor IX (FIX) polypeptide. The present invention also provides lyophilization methods for producing lyophilate powder comprising a FIX polypeptide.Type: GrantFiled: August 17, 2020Date of Patent: October 29, 2024Assignee: BIOVERATIV THERAPEUTICS INC.Inventors: Brian M. Thome, Cherie Parkhurst-Lang, Brandon W. Leveille
-
Patent number: 12084475Abstract: Provided herein are methods for site-specific conjugation of glycan intact antibodies by a transglutaminase. According to particular embodiments, the reaction conditions are maintained or reduced to a low-ionic strength condition, which allows for efficient and fast conjugation without the need for antibody deglycosylation. Also described are pharmaceutical compositions and uses related to the conjugation method.Type: GrantFiled: May 19, 2021Date of Patent: September 10, 2024Assignee: Janssen Biotech, Inc.Inventors: Vadim Dudkin, Shalom Goldberg, Michael J. McCauley, Kristen Wiley
-
Patent number: 12084403Abstract: In one aspect, the present disclosure provides compounds of the formula: wherein the variables are as defined herein. In another aspect, the present disclosure provides compounds of the formula: wherein the variables are as defined herein. In another aspect, the present disclosure also provides methods of preparing the compounds disclosed herein. In another aspect, the present disclosure provides antibody drug conjugates comprising compounds of the present disclosure. In another aspect, the present disclosure also provides pharmaceutical compositions and methods of use of the compounds and anti-body drug conjugates disclosed herein.Type: GrantFiled: February 23, 2023Date of Patent: September 10, 2024Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventors: Kyoji Tsuchikama, Yasuaki Anami, Chisato Tsuchikama, Ningyang Zhang, Zhiqiang An
-
Patent number: 11987634Abstract: The present invention provides antibodies that specifically bind to CD70 (Cluster of Differentiation 70). The invention further provides bispecific antibodies that bind to CD70 and another antigen (e.g., CD3). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific). The invention further relates to therapeutic methods for use of these antibodies for the treatment of CD70-mediated pathologies, including cancer.Type: GrantFiled: June 1, 2022Date of Patent: May 21, 2024Assignee: PFIZER INC.Inventors: Siler Panowski, Tao Sai, Barbra Johnson Sasu, Surabhi Srivatsa Srinivasan, Thomas John Van Blarcom
-
Patent number: 11944689Abstract: Compounds and compositions are disclosed in which a Drug Unit is linked to a targeting Ligand Unit through a self-stabilizing Linker Unit from which a drug compound or active drug moiety is released at the targeted site of action. Methods for treating diseases characterized by the targeted abnormal cells, such as cancer or an autoimmune disease using the compounds and compositions of the invention are also disclosed.Type: GrantFiled: August 9, 2017Date of Patent: April 2, 2024Assignee: Seagen Inc.Inventor: Philip Moquist
-
Patent number: 11897959Abstract: An antibody or antibody fragment having a heavy chain variable region and/or light chain variable region that specifically binds to Axl protein. Immuoconjugages, pharmaceutical compositions and kits comprising the antibodies and antibody fragments are also provided. Also disclosed are methods of treating Axl-expressing cancers using the antibodies, antibody fragments, immunoconjugates and pharmaceutical compositions of the present invention.Type: GrantFiled: September 3, 2021Date of Patent: February 13, 2024Assignee: BIOATLA, INC.Inventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
-
Patent number: 11826087Abstract: Treatment of skin tissue with photoactive materials and light, such as nanoparticles and formulations which are useful for cosmetic, diagnostic and therapeutic applications to mammals such as humans. In particular, embodiments of thermal treatment of the skin surface with metal nanoparticles in surfactant containing solutions are disclosed.Type: GrantFiled: September 16, 2016Date of Patent: November 28, 2023Assignee: Coronado Aesthetics, LLCInventors: Todd James Harris, Alice Ann Chen Kim
-
Patent number: 11707437Abstract: Nanoparticles comprising resiniferatoxin (RTX) encapsulated in a poly(lactic-co-glycolic acid) (PLGA) polymer and compositions, especially topical compositions, comprising the nanoparticles. The compositions can be used as topical formulations for ameliorating pain, including for diabetic patients with peripheral neuropathy.Type: GrantFiled: July 10, 2020Date of Patent: July 25, 2023Assignees: BOARD OF TRUSTEES OF SOUTHERN ILLINOIS UNIVERSITY, UNIVERSITY OF WYOMINGInventors: Louis Premkumar, Baskaran Thyagarajan
-
Patent number: 11708422Abstract: Inhibition of human epidermal growth factor receptor 2, human epidermal growth factor receptor 3, or of the heterodimerization of these proteins has presently been found to mitigate mechanically-induced lung injury or a lung-stretch injury. Provided are methods for treating a mechanically-induced lung injury or a lung-stretch injury, for increasing lung compliance, moderating alveolar epithelial permeability, or both in a subject having a mechanically-induced lung injury or a lung-stretch injury, for protecting a subject against a decrease in lung compliance, an increase in alveolar epithelial permeability, or both, as a result of a mechanically-induced lung injury or a lung-stretch injury, such methods involving the administration of an inhibitor of human epidermal growth factor receptor 2 (HER2) or human epidermal growth factor receptor 3 (HER3), or an inhibitor of the heterodimerization of HER2/HER3.Type: GrantFiled: May 28, 2020Date of Patent: July 25, 2023Assignee: The Trustees of the University of PennsylvaniaInventors: Susan S. Margulies, Nadir Yehya
-
Patent number: 11607460Abstract: The present invention is directed to methods for treating cancer comprising administering to a subject in need thereof an auristatin-based antibody drug conjugate and an inhibitor of the PI3K-AKT-mTOR pathway.Type: GrantFiled: December 19, 2018Date of Patent: March 21, 2023Assignee: SEAGEN INC.Inventors: Timothy S. Lewis, Che-Leung Law, Julie A. McEarchern
-
Patent number: 11441172Abstract: The present disclosure provides systems and methods for making a hydrogel comprising a cell, cell nucleus, or one or more components derived from a cell or cell nucleus. A method for making a hydrogel may comprise providing a cell or cell nucleus, a first polymer, wherein the first polymer comprises a plurality of first crosslink precursors, each of the plurality of first crosslink precursors comprising an azide group; providing a second polymer, wherein the second polymer comprises a plurality of second crosslink precursors, each of the plurality of second crosslink precursors comprising an alkyne group; and crosslinking the first polymer and the second polymer via a reaction between a first section of the first crosslink precursors and a second section of the second crosslink precursors, thereby providing the hydrogel comprising the cell or cell nucleus.Type: GrantFiled: September 1, 2020Date of Patent: September 13, 2022Assignee: 10x Genomics, Inc.Inventors: Joshua Delaney, Shalini Gohil, Christopher Hindson, Adam Lowe, Andrew D. Price, Joseph Francis Shuga
-
Patent number: 11261227Abstract: A glucagon derivative, a long-acting conjugate of the glucagon derivative, and a use thereof are disclosed.Type: GrantFiled: March 6, 2020Date of Patent: March 1, 2022Assignee: HANMI PHARM. CO., LTD.Inventors: Jung Kuk Kim, Young Jin Park, In Young Choi, Sung Youb Jung
-
Patent number: 11253586Abstract: Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.Type: GrantFiled: March 18, 2021Date of Patent: February 22, 2022Assignee: Novavax, Inc.Inventors: Gale Smith, Michael J. Massare, Jing-Hui Tian
-
Patent number: 11236177Abstract: The invention relates to proximity-based sortase-mediated protein purification and ligation. Specifically, the invention relates to techniques that links protein expression/purification with conjugation to therapeutic agents, imaging agents, or linkers.Type: GrantFiled: September 14, 2017Date of Patent: February 1, 2022Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: Andrew Tsourkas, Burcin Altun, Hejia Henry Wang, Feifan Yu
-
Patent number: 11149088Abstract: A polypeptide having a heavy chain variable region and/or light chain variable region that specifically binds to Axl protein as well as antibodies and antibody fragments containing the heavy chain variable region and/or the light chain variable region that bind to Axl protein. Pharmaceutical compositions and kits comprising the polypeptide or antibodies and antibody fragments containing the polypeptide are also provided.Type: GrantFiled: April 13, 2017Date of Patent: October 19, 2021Assignee: BioAtla, Inc.Inventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
-
Patent number: 11065319Abstract: Methods and products for diagnosing, treating and/or delaying onset of chronic allograft rejection, including cardiac allograft vasculopathy. In an exemplary embodiment of a noninvasive method of screening a cardiac allograft recipient for being at-risk for developing cardiac allograft vasculopathy of the present disclosure, the method comprises the steps of withdrawing at least one biological sample from a cardiac allograft recipient; and analyzing the at least one biological sample for one or more biomarkers indicative of the presence of fibrin deposits within the cardiac allograft microvasculature; wherein detection of the one or more biomarkers indicates that the cardiac allograft recipient is at-risk for or developing cardiac allograft vasculopathy.Type: GrantFiled: October 20, 2017Date of Patent: July 20, 2021Assignee: 3DT Holdings, LLCInventors: Ghassan S. Kassab, Carlos A. Labarrere
-
Patent number: 10980890Abstract: Provided herein are compounds comprising a self-immolative group, and the compounds comprising a self-immolative group according to the present invention may include a protein (for example, an oligopeptide, a polypeptide, an antibody, or the like) having substrate-specificity for a target and an active agent (for example, a drug, a toxin, a ligand, a detection probe, or the like) having a specific function or activity.Type: GrantFiled: August 20, 2019Date of Patent: April 20, 2021Assignee: LegoChem Biosciences, Inc.Inventors: Yong Zu Kim, Tae Kyo Park, Sung Ho Woo, Sun Young Kim, Jong Un Cho, Doo Hwan Jung, Ji Young Min, Hyang Sook Lee, Yun Hee Park, Jeong Hee Ryu, Kyu Man Oh, Yeong Soo Oh, Jeiwook Chae, Ho Young Song, Chul-Woong Chung, Jeon Yang
-
Patent number: 10953089Abstract: Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.Type: GrantFiled: August 19, 2020Date of Patent: March 23, 2021Assignee: NOVAVAX, INC.Inventors: Gale Smith, Michael J. Massare, Jing-Hui Tian
-
Patent number: 10894089Abstract: The present invention relates to insulin and/or an insulin analogue conjugate, and a use thereof, wherein the insulin and/or insulin analogue have improved in vivo durability and stability by linking the same with an Fc region of immunoglobulin. The insulin and/or an insulin analogue conjugate of the present invention show an in vivo activity similar to that of insulin. In addition, the insulin and/or insulin analogue conjugate of the present invention are long-acting formulations of insulin and/or the analogue thereof, in which serum half-life is remarkably increased, and therefore, the present invention provides remarkable insulin and/or an insulin analogue conjugate, which do not induce hypoglycemia, a drawback of insulin treatment.Type: GrantFiled: February 17, 2016Date of Patent: January 19, 2021Assignee: HANMI PHARM. CO., LTD.Inventors: Yong Ho Heo, Jong Soo Lee, Sung Hee Park, Dae Jin Kim, Sung Youb Jung, Se Chang Kwon
-
Patent number: 10871490Abstract: The invention is directed to a detection reagent for CAR expressing cells according to general formula (1) Xn—Sm—Do wherein X is a polypeptide comprising at least 20 amino acids of which at least two amino acids are connected by at least one disulfide group S is a spacer comprising at least 15 carbon atoms D is a detection moiety m, o are integers independently between 1 and 200 n is an integer between 4 and 200 with the provisio that X binds to the antigen binding domain of a chimeric antigen receptor of a cell. The detection agent can be used in a method to detect cells having an antigen binding domain of a chimeric antigen receptor (CAR) binding the detection reagent and preferable to remove the detection moiety D from the detected cell.Type: GrantFiled: January 27, 2017Date of Patent: December 22, 2020Assignee: Multenyi Biotec, gmbHInventors: Anne Richter, Michaela Niemoller, Volker Nolle, Stefan Miltenyi, Mario Assenmacher
-
Patent number: 10864277Abstract: The present invention relates to a method of producing an immunoligand/payload conjugate, which method encompasses conjugating a payload to an immunoligand by means of a sequence-specific transpeptidase, or a catalytic domain thereof.Type: GrantFiled: November 21, 2017Date of Patent: December 15, 2020Assignee: NBE Therapeutics AGInventors: Ulf Grawunder, Roger Renzo Beerli
-
Patent number: 10851157Abstract: Antitumor antagonists that bind specifically to immune checkpoint regulators, angiogenesis pathway regulators and/or TGF pathway regulators are disclosed. Also disclosed are methods for treating proliferative disorders, infections, and immunological disorders with the antitumor antagonists described herein.Type: GrantFiled: December 6, 2019Date of Patent: December 1, 2020Assignee: Gensun Biopharma, Inc.Inventors: Margaret Karow, Jackie Sheng, Wei Zhang
-
Patent number: 10792342Abstract: Methods of making ligand-decorated polymer conjugates of therapeutic glycoproteins are described. Improved targeting of glycoproteins to specific tissues is achieved by masking the natural carbohydrate and other surface determinants with high molecular weight polymers, such as, e.g., PEG, polysialic acid, etc., which in turn are decorated with target-specific ligands. In some embodiments, acid-labile linkages in such conjugates or rapidly degradable masking groups allow for the intracellular release of the polymer from the glycoprotein, for example, under conditions found in lysosomes.Type: GrantFiled: July 27, 2018Date of Patent: October 6, 2020Assignee: Genzyme CorporationInventor: James Stefano
-
Patent number: 10787480Abstract: Disclosed herein are novel cytotoxic peptides of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel cytotoxic peptide linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.Type: GrantFiled: June 12, 2019Date of Patent: September 29, 2020Assignee: Novartis AGInventors: Bernhard Hubert Geierstanger, Jan Grunewald, Yunho Jin, Weijia Ou, Tetsuo Uno, Yongqin Wan, Xing Wang
-
Patent number: 10751422Abstract: Antibody drug conjugates (ADC's) that bind to FLT3 protein and variants thereof are described herein. FLT3 exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.Type: GrantFiled: March 9, 2016Date of Patent: August 25, 2020Assignee: AGENSYS, INC.Inventors: Nandini Rudra-Ganguly, Christine Lowe, Faisal Hayat Malik, Sung Ju Moon, Josh Snyder, Hector Avina, Cyrus Virata, Linnette Capo, Gao Liu
-
Patent number: 10676773Abstract: An antibody has at a heavy chain thereof a C-terminal extension that includes at least one glutamine that is a substrate for transglutaminase, enabling the transglutaminase-mediated preparation antibody-drug conjugates using such antibody.Type: GrantFiled: March 1, 2016Date of Patent: June 9, 2020Assignee: Bristol-Myers Squibb CompanyInventors: Chetana Rao-Naik, Shrikant Deshpande
-
Patent number: 10668181Abstract: A surgical sealant consisting of (1) a first agent comprising a gelatin derivative, wherein the gelatin derivative (a) has a weight average molecular weight of from 10,000 to 50,000; (b) has a hydrophobic group bonded thereto, the hydrophobic group being an alkyl group having 6 to 18 carbon atoms; (c) has a molar ratio of imino group/amino group of the gelatin derivative ranging from 1/99 to 30/70; and (d) comprises a structure represented by the following formula: GltnNH—CHR1R2, wherein “Gltn” represents a gelatin residue, R1 is the hydrophobic group, and R2 is a hydrogen atom or the hydrophobic group; and (2) a second agent comprising a crosslinking agent for the gelatin derivative.Type: GrantFiled: January 11, 2017Date of Patent: June 2, 2020Assignee: NATIONAL INSTITUTE FOR MATERIALS SCIENCEInventor: Tetsushi Taguchi
-
Patent number: 10654924Abstract: Binding molecules to IL-17A. The binding molecules are useful in the treatment of disorders, for example psoriasis.Type: GrantFiled: January 12, 2016Date of Patent: May 19, 2020Assignee: CRESCENDO BIOLOGICS LIMITEDInventors: Bryan Edwards, Ulla Lashmar, Brian McGuinness, Mike Romanos, Thomas Sandal, Yumin Teng
-
Patent number: 10647745Abstract: The present invention provides a compound (I) for treating sequelae of ischemic cerebral stroke: H—(NH—CHR1—CO)—(NH—CHR2—CO)—(NH—CHR3—CO)—(NH—CHR4—CO)—(NH—CHR5—CO)—(NH—CHR6—CO)—(NH—CHR7—CO)—OH??(I) or a pharmaceutically acceptable salt thereof, wherein R1-R7 are defined herein. The present invention also provides a pharmaceutical composition comprising said compound and use of the same in the manufacture of a medicament for treating sequelae of ischemic cerebral stroke. The compound and pharmaceutical composition according to the present invention have good pharmacological activities so that they are able to improve significantly the symptom of sequelae of ischemic cerebral stroke.Type: GrantFiled: August 9, 2018Date of Patent: May 12, 2020Inventor: Jingyi Wang
-
Patent number: 10639382Abstract: The present disclosure relates to methods of reducing the number of abnormal PBMC cells in a leukemia patient. The methods may include administering an effective amount of a drug, which may not be indicated for leukemia, or an antibody-drug conjugate. The antibody-drug conjugate includes an antibody selected from the group consisting of an anti-?2-adrenoreceptor antibody, an anti-? adrenoceptor antibody, an anti-trace amine-associated receptor 1 antibody, an anti-dopamine receptor antibody, and an anti-serotonin receptor antibody; a drug selected from the group consisting of isoproterenol, methyldopa, olanzapine, and a derivative thereof; and a linker that conjugates the antibody and the drug.Type: GrantFiled: April 13, 2017Date of Patent: May 5, 2020Assignees: National Guard Health Affairs, King Saud bin Abdulaziz University for Health Services, King Abdullah International Medical Research CenterInventors: Mohamed Boudjelal, Atef Nehdi, Ahmed Sulaiman Alaskar, Imadul Islam, Hajar Mohammed Alzahrani
-
Patent number: 10617670Abstract: This invention relates to combinations of an auristatin or an auristatin-based antibody-drug-conjugate (ADC) with second active agents including PI3K/mTOR inhibitors, MEK inhibitors, taxanes, or other anti-cancer agents, and methods of treating abnormal cell growth by administering these combinations to patients.Type: GrantFiled: September 29, 2015Date of Patent: April 14, 2020Assignee: Pfizer Inc.Inventors: Puja Sapra, Boris Shor
-
Patent number: 10578577Abstract: Embodiments of the invention are directed to a solid-state zinc sensor. A non-limiting example of the sensor includes a semiconductor substrate. The sensor can also include an assembly surface on the semiconductor substrate. The sensor can also include a zinc detection monolayer chemically bound to the assembly surface. The sensor can also include a power supply electrically connected to the semiconductor substrate.Type: GrantFiled: June 28, 2017Date of Patent: March 3, 2020Assignee: INTERNATIONAL BUSINESS MACHINES CORPORATIONInventors: Ali Afzali-Ardakani, Abram L. Falk, Bharat Kumar
-
Patent number: 10443026Abstract: A polygonal scaffold includes at least three polyproline II (PPII) helix rods and at least three connectors. Each of the PPII helix rods is composed of a plurality of repeat units represented by Formula (i), and at least one of the PPII helix rods has at least one hydrogen atom of at least one of the repeat units being substituted by a first chemical handle for connecting a ligand. Each of the connectors is a divalent organic group, and every two of the PPII helix rods are connected by one of the connectors to form a closed ring. Therefore, with the uniform composition, the PPII helix rods have a stable helical structure under aqueous conditions, and a desired rigidity can be provided.Type: GrantFiled: December 25, 2017Date of Patent: October 15, 2019Assignee: NATIONAL TSING HUA UNIVERSITYInventors: Sheng-Kai Wang, Cin-Hao Lin
-
Patent number: 10307391Abstract: The present invention relates to novel disulfur bridge linkers containing hydrazine used for the specific conjugation of compounds/cytotoxic agents to a cell-binding molecule, through bridge linking a pair of thiols on the cell-binding molecule. The invention also relates to methods of making such linkers, and of using such linkers in making homogeneous conjugates, as well as of application of the conjugates in treatment of cancers, infections and autoimmune disorders.Type: GrantFiled: April 5, 2017Date of Patent: June 4, 2019Assignee: HANGZHOU DAC BIOTECH CO., LTD.Inventor: Robert Yongxin Zhao
-
Patent number: 10307488Abstract: Disclosed are novel antibody-drug conjugates and use thereof in therapy, in particular in anticancer or anti-inflammatory therapy, as well as synthetic products useful as linkers, composed of a linker head and a linker body, and also a method for preparing the linkers and the antibody-drug conjugates.Type: GrantFiled: July 11, 2014Date of Patent: June 4, 2019Assignee: UNIVERSITE FRANCOIS RABELAISInventors: Nicolas Joubert, Marie Claude Viaud-Massuard, Renaud Respaud
-
Patent number: 10265291Abstract: The present invention relates to novel disulfur bridge linkers containing hydrazine used for the specific conjugation of compounds/cytotoxic agents to a cell-binding molecule, through bridge linking a pair of thiols on the cell-binding molecule. The invention also relates to methods of making such linkers, and of using such linkers in making homogeneous conjugates, as well as of application of the conjugates in treatment of cancers, infections and autoimmune disorders.Type: GrantFiled: February 13, 2017Date of Patent: April 23, 2019Assignee: HANGZHOU DAC BIOTECH CO., LTD.Inventor: Robert Yongxin Zhao
-
Patent number: 10215727Abstract: Embodiments of the invention are directed to a solid-state zinc sensor. A non-limiting example of the sensor includes a semiconductor substrate. The sensor can also include an assembly surface on the semiconductor substrate. The sensor can also include a zinc detection monolayer chemically bound to the assembly surface. The sensor can also include a power supply electrically connected to the semiconductor substrate.Type: GrantFiled: November 2, 2017Date of Patent: February 26, 2019Assignee: INTERNATIONAL BUSINESS MACHINES CORPORATIONInventors: Ali Afzali-Ardakani, Abram L. Falk, Bharat Kumar
-
Patent number: 10201615Abstract: The present invention is directed to methods for treating cancer comprising administering to a subject in need thereof an auristatin-based antibody drug conjugate and an inhibitor of the PI3K-AKT-mTOR pathway.Type: GrantFiled: January 27, 2016Date of Patent: February 12, 2019Assignee: SEATTLE GENETICS, INC.Inventors: Timothy S. Lewis, Che-Leung Law, Julie A. McEarchern
-
Patent number: 10159745Abstract: Novel tubulysin derivatives which may be useful as cytotoxic agents to provide therapeutic benefits in the treatment of various types of cancers, alone, as drug conjugates or in combination with other chemotherapies are provided.Type: GrantFiled: August 8, 2016Date of Patent: December 25, 2018Assignee: MedImmune, LLCInventors: Lakshmaiah Gingipalli, Dorin Toader, Fengjiang Wang
-
Patent number: 10118966Abstract: The present invention provides a method for producing an anti-EGFR monoclonal antibody and the applications thereof. The method comprises the steps of: designing and synthesizing the light chain and heavy chain according to the codons preferred by Chinese hamster, transfecting GS knockout host cells CHO-CR-GS?/?, culturing cells using serum-free technology, isolating and purifying the antibody, and obtaining the low immunogenicity CMAB009 antibody.Type: GrantFiled: January 4, 2016Date of Patent: November 6, 2018Assignee: Shanghai Biomabs Pharmaceuticals Co., Ltd.Inventor: Weizhu Qian
-
Patent number: 10117947Abstract: The present disclosure is directed to methods and compositions for the diagnosis and/or treatment of tumors, such as ocular tumors, using virus-like particles conjugated to photosensitive molecules.Type: GrantFiled: September 18, 2014Date of Patent: November 6, 2018Assignees: Aura Biosciences, Inc., The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Elisabet de los Pinos, John Todd Schiller, Rhonda C. Kines, John MacDougall
-
Patent number: 9943615Abstract: Disclosed herein are nanoparticles and method for manufacturing the same. The nanoparticle is essentially composed of albumin and polyethylene glycol, wherein the albumin is covalently crosslinked with the polyethylene glycol.Type: GrantFiled: November 13, 2015Date of Patent: April 17, 2018Assignee: INSTITUTE OF NUCLEAR ENERGY RESEARCH ATOMIC ENERGY COUNCIL, EXECUTIVE YUAN R.O.CInventors: Su-Jung Chen, Chang-An Chen, Chung-Yen Li, Chu-Nian Cheng, Ming-Syuan Lin, Shu-Pei Chiu, Chih-Hsien Chang
-
Patent number: 9939447Abstract: Compositions, kits, and methods are disclosed for determining one or more target polypeptides in a sample where the target polypeptides have undergone a post-translational modification. The compositions can include a first reagent including a cleavage-inducing moiety and a first binding agent for a binding site that includes a post-translational modification of a target polypeptide.Type: GrantFiled: August 14, 2015Date of Patent: April 10, 2018Assignee: Monogram Biosciences, Inc.Inventors: Sharat Singh, Hossein Salimi-Moosavi, Syed Hasan Tahir, Gerald J. Wallweber, Hrair Kirakossian, Tracy J. Matray, Vincent S. Hernandez
-
Patent number: 9895450Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.Type: GrantFiled: November 19, 2015Date of Patent: February 20, 2018Assignee: Genentech, Inc.Inventors: Eric J. Brown, John Flygare, Wouter Hazenbos, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
-
Patent number: 9884126Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.Type: GrantFiled: May 22, 2014Date of Patent: February 6, 2018Assignee: Genentech, Inc.Inventors: Eric J. Brown, John Flygare, Wouter Hazenbos, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
-
Patent number: 9878041Abstract: A tissue adhesive including cyanoacrylate and polyethylene glycol (PEG), wherein the PEG remains a polyether and wherein the tissue adhesive is bioabsorbable. A tissue adhesive including cyanoacrylate bulk monomer and cyanoacrylate nanoparticles containing a therapeutic therein. A kit for applying tissue adhesive, including the tissue adhesive described above and an applicator. Methods of accelerating degradation of a cyanoacrylate tissue adhesive applying a tissue adhesive, closing an internal wound, administering a therapeutic to tissue, treating cancer, and preventing infection in a wound. Methods of method of making a bioabsorbable tissue adhesive and making a therapeutic tissue adhesive.Type: GrantFiled: November 8, 2013Date of Patent: January 30, 2018Assignee: Adhezion Biomedical, LLCInventors: Jeoung Soo Lee, Charles Kenneth Webb, Robert Zimmerman, Rafael Ruiz, Sr., Sheng Zhang